Dr. Lynn R. Kong, MD

Dr. Kong practices at St. John's Outpatient Surgery Center, LP in Oxnard, California.

Dr. Kong's NPI, 1952356933, was assigned on May 24, 2006. Dr. Kong graduated from Feinberg School of Medicine in 1991. Dr. Kong holds California license G83707.

Dr. Kong's primary practice is St. John's Outpatient Surgery Center, LP, at 1700 N Rose Ave, Oxnard, CA 93030 in Ventura County. The practice phone is (805) 204-5000.

Dr. Kong's primary practice is St. John's Outpatient Surgery Center, LP in Oxnard, California. Dr. Kong is also affiliated with Dignity Health - St. John's Regional Medical Center. The medical group on file is Ventura County Hematology-Oncology Specialists. Dmand AI also links Dr. Kong to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kong practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kong's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kong is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kong's licenses on file in 2 states: California and Illinois.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Kong treats.

CMS data shows 9,516 Medicare services from Dr. Kong across 14 procedure codes in 2024, for 855 Medicare patients. Medicare paid $347,756 for them.

CMS counts 855 Medicare patients who saw Dr. Kong in 2024. The largest group is 75 to 84, with 354 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kong's median patient age at 72, with 70% women.

In 2024, Dr. Kong wrote 1,092 Medicare Part D claims for 195 patients. 69% of them were for generic drugs. CMS names the drug for 856 of them, across 26 drugs with 11 or more claims each, at $3,079,269 in total drug cost. In 2023, CMS named 844 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Kong for performance year 2024, reported individually. Dr. Kong accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kong as offering telehealth.

Dmand AI links 6 papers to Dr. Kong, published from 2022 to 2024. 2022 was the busiest year, with 2. The most frequent topics are Ovarian Neoplasms. Dr. Kong's most frequent co-authors are Joyce N. Barlin, MD, Brad David Barrows, DO and Eduardo D. Bruera, MD.

Dmand AI links Dr. Kong to 4 clinical trials, 2 of them phase 2 studies. Conditions studied include Breast Neoplasms, Breast Diseases and Lymphoma, T-Cell. Novartis Pharmaceuticals sponsors the most, 3.

CMS Open Payments shows 1,002 general payments to Dr. Kong from 75 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,309.

Dmand AI lists 1 award for Dr. Kong, most recently CMS Stage 1 2012 in 2012.

Dr. Kong graduated from Feinberg School of Medicine in 1991. Dr. Kong is a member of ACP, ASCO and ASH.

Dr. Kong is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.